SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Johnson & Weaver, LLP has commenced an investigation into whether certain officers and directors of Halozyme Therapeutics, Inc. (NASDAQ: HALO) violated state or federal laws. Halozyme is a biopharmaceutical company that researches, develops and commercializes human enzymes.
On April 9, 2014, Halozyme announced that the U.S. Food and Drug Administration had placed a clinical hold on patient enrollment and dosing of PEGPH20 in patients with pancreatic cancer. Just a few days earlier on April 4, 2014, Halozyme issued a statement announcing that the Phase 2 trial for PEGPH20 would be halted. The suspension of the trial followed the recommendation of an independent Data Monitoring Committee (DMC) while it assesses "clinical data that indicates a possible difference in the thromboembolic event rate between the group of patients treated with PEGPH20, nab-paclitaxel and gemcitabine versus the group of patients treated with nab-paclitaxel and gemcitabine without PEGPH20." Since April 4, 2014, Halozyme shares have fallen $4.02, or 35%, to close at $7.57 on April 17, 2014.
If you are a Halozyme shareholder and are interested in learning more about the investigation or your legal rights and remedies, please contact Jim Baker (email@example.com) at 619-814-4471. If you email, please include your phone number.
Johnson & Weaver, LLP is a nationally recognized shareholder rights law firm with offices in California and New York. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonandweaver.com. Attorney advertising. Past results do not guarantee future outcomes.